Vascular Disruptive Agents for the Treatment of Cancer

  • Tim Meyer

Table of contents

  1. Front Matter
    Pages i-ix
  2. Pre-Clinical Development

    1. Front Matter
      Pages 29-29
    2. Graeme J. Dougherty, David J. Chaplin
      Pages 1-27
  3. Pre-Clinical Development

    1. Front Matter
      Pages 29-29
    2. Giulia Taraboletti, Katiuscia Bonezzi, Raffaella Giavazzi
      Pages 77-93
    3. Lesley D. McPhail, Simon P. Robinson
      Pages 95-116
    4. Yuval Shaked, Paul Nathan, Laura G. M. Daenen, Robert S. Kerbel
      Pages 117-134
  4. Imaging in the Development of Vascular Disruptive Agents

    1. Front Matter
      Pages 135-135
    2. Martin Zweifel, Anwar R. Padhani
      Pages 137-163
    3. Grzegorz Korpanty, Rolf A. Brekken
      Pages 165-179
  5. Clinical Development

    1. Front Matter
      Pages 181-181
    2. Henry C. Mandeville, Peter J. Hoskin
      Pages 231-250
  6. Back Matter
    Pages 251-256

About this book


Tumour survival and growth is critically dependent on an independent blood supply. As such tumour vasculature presents an ideal target for cancer therapy that is widely applicable, accessible and genetically stable rendering it less prone to resistance. Two approaches have been explored for cancer therapy; firstly the prevention of new vessel formation with inhibitors of angiogenesis, and secondly the destruction of existing tumour blood vessels with so called vascular disruptive agents (VDAs). While the first approach appears to delay tumour progression, the second has the potential to cause massive cell death and tumour regression. It is the second approach of vascular targeting that is the focus of this book. Since the tubulin binding agent combretastatin, derived from the bark of the African bush willow, was discovered by George R Pettit to have antimitotic properties over twenty years ago, the field of vascular targeting has expanded steadily. Coincident with the preclinical and clinical development of these agents, there have been advances in our understanding of their mechanism of action and in the technology required to assess their effects. This book aims to provide a comprehensive account of the current state of the art. Preclinical target identification and validation are discussed and the optimum pre-clinical animal models described. The imaging modalities that can be used to assess the efficacy of these agents are examined and a comprehensive review of the clinical development of key drugs is provided. Finally, the recent research exploring rational combinations of VDAs with other agents is reviewed and the potential place of VDAs in the future of cancer therapy is critically appraised.


CT angiogenesis cancer cancer therapy cell cell death chemotherapy computed tomography (CT) imaging magnetic resonance imaging (MRI) prevention radiotherapy research resistance tumor

Editors and affiliations

  • Tim Meyer
    • 1
  1. 1.Cancer InstituteUniversity College LondonLondonUnited Kingdom

Bibliographic information